Efficacy, Safety, and Tolerability of Quetiapine in Patients with Schizophrenia.
- Author:
Chan Hyung KIM
1
;
Young Kee KIM
Author Information
1. Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Atypical antipsychotics;
Quetiapine;
Schizophrenia
- MeSH:
Antipsychotic Agents;
Humans;
Korea;
Schizophrenia*;
United States
- From:Korean Journal of Psychopharmacology
2004;15(2):135-143
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Atypical antipsychotics have an improved tolerability profile, and are less likely to cause debilitating extrapyramidal symptoms (EPS) than are the conventional antipsychotics. Quetiapine, the fourth atypical antipsychotic, was marketed in Korea as well as in the United States and is also available in over 70 countries worldwide. Quetiapine has been shown to be effective and well tolerated in patients particularly vulnerable to EPS related to conventional antipsychotics. In this article, we review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in treating patients with schizophrenia.
